and adult patients with pku FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T222116ZBuilt
We track 1 and adult patients with pku drug. No FDA approvals recorded yet.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| Sephience™ (sepiapterin) | PTCT | — | Orphan Drug |
Upcoming catalysts
No events in this view.
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jul 2024Month disclosed | Sephience™ (sepiapterin) | PTCT | NDA/BLA submission | and adult patients with PKU | Completed | SEC Form 10-Q |
All indications · Approval rates by indication
Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.
Questions
What and adult patients with pku drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.